

Alvaro Lassaletta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8560675/publications.pdf>

Version: 2024-02-01

50
papers

2,768
citations

361413

20
h-index

223800

46
g-index

55
all docs

55
docs citations

55
times ranked

4047
citing authors

#	ARTICLE	IF	CITATIONS
1	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
2	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
3	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	16.8	244
4	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	1.6	232
5	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	12.8	200
6	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
7	Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3537-3543.	1.6	157
8	Functional and neuropsychological late outcomes in posterior fossa tumors in children. <i>Child's Nervous System</i> , 2015, 31, 1877-1890.	1.1	76
9	Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2038-2041.	1.5	57
10	Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26988.	1.5	51
11	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	4.1	49
12	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
13	Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 562-570.	1.7	39
14	Neuropsychological Profile in Children with Posterior Fossa Tumors with or Without Postoperative Cerebellar Mutism Syndrome (CMS). <i>Cerebellum</i> , 2020, 19, 78-88.	2.5	32
15	Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS-CoV-2 pandemic. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28557.	1.5	31
16	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. <i>Human Genetics</i> , 2016, 135, 469-475.	3.8	29
17	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. <i>Child's Nervous System</i> , 2016, 32, 1789-1797.	1.1	26
18	Medulloblastoma in adults: they're not just big kids. <i>Neuro-Oncology</i> , 2016, 18, 895-897.	1.2	23

#	ARTICLE	IF	CITATIONS
19	Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child. <i>Journal of Neuro-Oncology</i> , 2007, 83, 303-306.	2.9	22
20	Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2009, 95, 65-69.	2.9	22
21	Volumetric assessment of tumor size changes in pediatric low-grade gliomas: feasibility and comparison with linear measurements. <i>Neuroradiology</i> , 2018, 60, 427-436.	2.2	22
22	Isolated optic nerve gliomas: a multicenter historical cohort study. <i>Journal of Neurosurgery: Pediatrics</i> , 2017, 20, 549-555.	1.3	17
23	Reversal of an Antihistamine-Induced Coma With Flumazenil. <i>Pediatric Emergency Care</i> , 2004, 20, 319-320.	0.9	14
24	Second re-irradiation for DIPG progression, re-considering "old strategies" with new approaches. <i>Child's Nervous System</i> , 2017, 33, 849-852.	1.1	14
25	The Latin American Brain Tumor Board teleconference: results of a web-based survey to evaluate participant experience utilizing this resource. <i>Child's Nervous System</i> , 2019, 35, 257-265.	1.1	13
26	Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. <i>Cancers</i> , 2020, 12, 1104.	3.7	12
27	Efficacy and safety of liposomal cytarabine in children with primary CNS tumours with leptomeningeal involvement. <i>Clinical and Translational Oncology</i> , 2012, 14, 280-286.	2.4	10
28	Real-world data for pediatric medulloblastoma: can we improve outcomes?. <i>European Journal of Pediatrics</i> , 2021, 180, 127-136.	2.7	8
29	Medulloblastoma in infants: the never-ending challenge. <i>Lancet Oncology</i> , The, 2018, 19, 720-721.	10.7	7
30	Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28089.	1.5	7
31	Follow-up evaluation of a web-based pediatric brain tumor board in Latin America. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29073.	1.5	7
32	A Persistent epidural mass in a child with B-lineage ALL. <i>Pediatric Blood and Cancer</i> , 2010, 55, 727-729.	1.5	4
33	DEV-14. IMPACT OF A LATIN AMERICA-WIDE TELECONFERENCED BRAIN TUMOR BOARD. <i>Neuro-Oncology</i> , 2018, 20, i47-i48.	1.2	4
34	Improving the quality of care in the molecular era for children and adolescents with medulloblastoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1687-1698.	2.4	4
35	Treatment of radiation-induced myelopathy with bevacizumab. <i>Clinical and Translational Oncology</i> , 2020, 22, 957-960.	2.4	4
36	Evaluation of the Pediatric Neuro-Oncology Resources Available in Chile. <i>JCO Global Oncology</i> , 2021, 7, 425-434.	1.8	3

#	ARTICLE	IF	CITATIONS
37	Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29365.	1.5	3
38	Relationship of BRAF V600E and associated secondary mutations on survival rate and response to conventional therapies in childhood low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10509-10509.	1.6	3
39	Old drugs still work! Oral etoposide in a relapsed medulloblastoma. <i>Child's Nervous System</i> , 2019, 35, 865-869.	1.1	3
40	Can monitoring asparaginase activity help us to manage toxicity in pediatric acute lymphoblastic leukemia?. <i>Leukemia and Lymphoma</i> , 2020, 61, 990-992.	1.3	2
41	Methotrexate-induced stroke-like neurotoxicity: Case report, 8 years of experience, and literature review. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29627.	1.5	2
42	HG-37SECOND RE-IRRADIATION FOR DIPG PROGRESSION, RE-CONSIDERING "OLD STRATEGIES" WITH NEW APPROACHES. <i>Neuro-Oncology</i> , 2016, 18, iii55.4-iii56.	1.2	1
43	LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2016, 18, iii82.3-iii82.	1.2	1
44	LGG-60. THE GENETIC LANDSCAPE OF PEDIATRIC LOW-GRADE GLIOMAS: INCIDENCE, PROGNOSIS AND RESPONSE TO THERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	1
45	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. <i>Journal of Personalized Medicine</i> , 2020, 10, 244.	2.5	1
46	Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2019-2019.	1.6	1
47	CMS-03RISK FACTORS FOR LONG TERM SPEECH DEFICITS IN CHILDREN WITH CEREBELLAR MUTISM SYNDROME. <i>Neuro-Oncology</i> , 2016, 18, iii16.3-iii16.	1.2	0
48	Imaging of metastatic medulloblastoma in the molecular era.. <i>Journal of Clinical Oncology</i> , 2016, 34, e22003-e22003.	1.6	0
49	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10503-10503.	1.6	0
50	Intracranial desmoplastic small round cell tumor after childhood acute myeloid leukemia treated with metronomic oral cyclophosphamide. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29687.	1.5	0